Get the Stockscreener App
10.22
2.29%
-0.24
Kura Oncology Inc stock is traded at $10.22, with a volume of 1.47M.
It is down -2.29% in the last 24 hours and down -4.31% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$10.46
Open:
$10.48
24h Volume:
1.47M
Relative Volume:
0.79
Market Cap:
$889.32M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-4.7097
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
-14.48%
1M Performance:
-4.31%
6M Performance:
+53.45%
1Y Performance:
+5.47%
1-Day Range:
$10.17
$10.56
1-Week Range:
$10.17
$12.31
52-Week Range:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
10.22 | 910.20M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
(KURA) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Kura Oncology, Inc. $KURA Shares Sold by Armistice Capital LLC - MarketBeat
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML - MSN
Insider Sell: Faheem Hasnain Sells 10,000 Shares of Kura Oncology Inc (KURA) - GuruFocus
Insiders Find Solace Selling US$1.4m In Stock With Kura Oncology's Price Down 11% - 富途牛牛
Kura Oncology stock maintains Market Outperform rating at Citizens By Investing.com - Investing.com Canada
Kura Oncology, Inc. (KURA) Fundamental Analysis - Meyka
Kura Oncology (KURA) Reports Promising AML Trial Results - GuruFocus
Kura Oncology, Kyowa Kirin Report 'Encouraging' Drug Combo Data to Treat Acute Myeloid Leukemia - marketscreener.com
Kura Oncology & Kyowa Kirin announce positive Komzifti combination data for acute myeloid - marketscreener.com
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - MSN
Kura Oncology (KURA) Reveals Positive Leukemia Treatment Data - GuruFocus
Kura Oncology and Kyowa Kirin Report Promising Data for KOMZIFTI in Combination Therapy for Acute Myeloid Leukemia at ASH 2025 - Quiver Quantitative
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - The Manila Times
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - marketscreener.com
Kura Oncology, Inc. $KURA Shares Sold by Walleye Capital LLC - MarketBeat
What analysts say about Kura Oncology Inc stockStock Buy Signals & Free Real-Time Trading Alerts Every Day - earlytimes.in
Price Clustering Detected in Bhaskar Agrochemicals Limited StockVolatility Index Analysis & Reap the Rewards of Patience + Planning - earlytimes.in
Why The Narrative Around Kura Oncology Is Shifting After Komzifti’s FDA Breakthrough - Yahoo Finance
Kura Oncology stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Franklin Resources Inc. Decreases Stake in Kura Oncology, Inc. $KURA - MarketBeat
FDA approved five NMEs in November - biocentury.com
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Kura Oncology (NASDAQ:KURA) Trading Up 7.3%What's Next? - MarketBeat
Kura Oncology: A Cautious Buy (NASDAQ:KURA) - Seeking Alpha
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - The Manila Times
Kura Oncology completes first commercial sale of leukemia drug By Investing.com - Investing.com Canada
Geode Capital Management LLC Purchases 211,470 Shares of Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology (NASDAQ: KURA) plans Dec. 8 webcast on ASH 2025 AML triplet study data - Stock Titan
Kura Oncology Announces First U.S. Sale of KOMZIFTI - MSN
Kura Oncology (KURA) Is Down 7.2% After First KOMZIFTI Sale Triggers $135M Milestone Payment - simplywall.st
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data (NASDAQ:KURA) - Seeking Alpha
Kura Oncology, Inc. Completes Collaboration and License Agreement with Kyowa Kirin - marketscreener.com
Kura Oncology Expects $135 Million Milestone Payment for First US Sale of Komzifti - marketscreener.com
Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment - Investing.com Nigeria
Kura Oncology (KURA) Secures $135 Million Milestone with KOMZIFT - GuruFocus
Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment By Investing.com - Investing.com South Africa
Kura Oncology completes first commercial sale of leukemia drug - Investing.com
First U.S. commercial sale of Komzift triggers $135 million milestone payment to Kura Oncology - marketscreener.com
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - The Manila Times
Kura Oncology (Nasdaq: KURA) to receive $135M as KOMZIFTI launches in U.S. market - Stock Titan
How Kura Oncology Inc. stock trades during market volatilityRate Hike & Daily Growth Stock Investment Tips - Newser
How geopolitical tensions affect Kura Oncology Inc. stockWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
How rising interest rates impact Kura Oncology Inc. stock - Newser
Is Megatherm Induction Limited Stock a Strong Buy According to Wall StreetLarge Cap Stability Picks & Free Unlock Stock Analysis - earlytimes.in
Rhenman & Partners Asset Management AB Boosts Stake in Kura Oncology, Inc. $KURA - MarketBeat
Magnetar Financial LLC Buys 64,345 Shares of Kura Oncology, Inc. $KURA - MarketBeat
Foresite Capital Management IV LLC Has $4.71 Million Holdings in Kura Oncology, Inc. $KURA - MarketBeat
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML) - The Manila Times
Kura Oncology’s leukemia drug added to NCCN treatment guidelines By Investing.com - Investing.com Australia
Kura Oncology’s leukemia drug added to NCCN treatment guidelines - Investing.com UK
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):